FGF21 and Hepatic fibrosis: In NAFLD patients, serum levels of chemokines CCL2 was associated with inflammation and advanced hepatic fibrosis, FGF21 was associated with inflammation;In murine models of NASH, CCR2/5 inhibition reduced circulating Ly6C(hi) MoMFs, and the FGF21 agonist reduced body weight, hepatic triglycerides.